A 35-year-old woman from Jharkhand presents with a 4-month history of fever, weight loss, and massive splenomegaly. Laboratory tests show hemoglobin 7.8 g/dL, WBC 3,200/μL, and platelets 80,000/μL. Bone marrow aspirate confirms visceral leishmaniasis. She is started on sodium stibogluconate 20 mg/kg/day intravenously for 30 days. After 2 weeks of therapy, she develops cardiac arrhythmias and QT prolongation on ECG. What is the most appropriate management?

Explanation

## Management of Sodium Stibogluconate Cardiotoxicity in Kala-azar ### Sodium Stibogluconate Toxicity Profile **Key Point:** Sodium stibogluconate (pentavalent antimony compound) is a first-line agent for visceral leishmaniasis but carries significant **cardiotoxicity** risk, manifesting as QT prolongation, arrhythmias, and myocarditis, especially after 2–3 weeks of therapy. **Warning:** QT prolongation with sodium stibogluconate is NOT reversible and self-limiting—it is a serious, dose-dependent adverse effect that can progress to life-threatening arrhythmias (Torsades de Pointes) and sudden cardiac death if not managed promptly. ### Treatment Options for Visceral Leishmaniasis | Agent | Mechanism | Efficacy | Cardiotoxicity | Use | |-------|-----------|----------|-----------------|-----| | **Sodium stibogluconate** | Pentavalent Sb; inhibits glycolysis | 90–95% in India | **High** (QT↑, arrhythmias) | First-line (if cardiac monitoring available) | | **Liposomal amphotericin B** | Polyene; disrupts ergosterol | 95–100% | **Minimal** | **Gold standard; preferred if cardiotoxicity develops** | | **Amphotericin B deoxycholate** | Polyene; disrupts ergosterol | 95–100% | Nephrotoxicity, infusion toxicity | Alternative (less tolerable) | | **Miltefosine** | Alkylphospholipid; apoptosis | 90–95% | Minimal | Oral option; teratogenic; slower response | | **Paromomycin** | Aminoglycoside | 70–80% | Ototoxicity, nephrotoxicity | Adjunctive or combination | **High-Yield:** When cardiotoxicity (QT prolongation, arrhythmias) develops during sodium stibogluconate therapy, **liposomal amphotericin B** is the safest and most effective alternative. It has: - Superior efficacy (95–100%) - Minimal cardiac toxicity - Rapid parasite clearance - Established safety in pregnancy ### Clinical Management Algorithm ```mermaid flowchart TD A["Visceral leishmaniasis diagnosed"]:::outcome --> B{"Cardiac risk factors or baseline ECG abnormality?"}:::decision B -->|"No"| C["Sodium stibogluconate 20 mg/kg/day IV x 30 days"]:::action B -->|"Yes"| D["Liposomal amphotericin B preferred"]:::action C --> E{"Monitor ECG at weeks 1-2-3"}:::decision E -->|"QT normal"| F["Continue stibogluconate"]:::action E -->|"QT prolongation or arrhythmia"| G["STOP stibogluconate immediately"]:::urgent G --> H["Switch to liposomal amphotericin B 3-5 mg/kg/day IV"]:::action D --> I["Complete 15-20 doses"]:::action H --> I I --> J["Assess cure at 6 months"]:::outcome ``` **Clinical Pearl:** Liposomal amphotericin B is encapsulated in liposomes, which preferentially accumulate in the reticuloendothelial system (spleen, liver, bone marrow) where parasites reside. This targeted delivery maximizes efficacy while minimizing systemic toxicity compared to conventional amphotericin B. **Mnemonic: LIPOSOMAL AMPHOTERICIN B ADVANTAGES — SAFE, FAST, EFFECTIVE:** - **S**afe (minimal cardiotoxicity, nephrotoxicity) - **A**ccumulates in RES (liver, spleen) - **F**ast parasite clearance - **E**ffective (95–100% cure) ### Why Other Options Are Incorrect 1. **Continuing stibogluconate:** QT prolongation is progressive and life-threatening. Continuing the offending agent risks sudden cardiac death. 2. **Dose reduction:** While lower doses reduce toxicity, they may compromise efficacy. Complete switch is safer. 3. **Miltefosine monotherapy:** Although miltefosine is oral and has minimal cardiac effects, it is slower-acting and less reliable than liposomal amphotericin B for acute cardiotoxicity. It is better reserved for patients who cannot tolerate IV therapy. [cite:Park 26e Ch 21; Harrison 21e Ch 297]